Introduction
============

POEMS syndrome (Crow-Fukase syndrome, Takatsuki syndrome) is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes ([@B1]-[@B3]). The various symptoms of this syndrome are thought to result from the high cytokinemia involving cytokines, such as vascular endothelial growth factor (VEGF), but the molecular pathology of the syndrome has not been sufficiently elucidated. In recent years, it has been reported that immunomodulatory drugs (IMiDs) targeting VEGF, such as thalidomide and lenalidomide, have good therapeutic effects for this condition ([@B4]-[@B6]).

The usefulness of detecting minimal residual disease (MRD) by multiparameter flow cytometry (MFC) has been reported in determining the therapeutic effect after treatment of multiple myeloma (MM) ([@B7]). However, the fraction of monoclonal plasma cells in POEMS syndrome is often small. Therefore, it is difficult to identify neoplastic plasma cells by conventional flow cytometry in patients with this syndrome ([@B8]).

All cases of POEMS syndrome reported so far have had the lambda-type monoclonal protein, except for four cases previously reported in the literature. We herein report a rare case of POEMS syndrome with IgG-kappa-type monoclonal protein, wherein a small number of neoplastic plasma cells were identified by MFC, and a good therapeutic effect was achieved by lenalidomide-dexamethasone (Ld) therapy.

Case Report
===========

A 72-year-old man was admitted to our hospital because of a 6-month history of systemic edema, pain in the legs, and anorexia. He had a surgical history of prostate cancer eight years ago. A physical examination showed the presence of pitting edema in both legs, hyperpigmentation, white nails, multiple small hemangiomas, gynecomastia, and papillary tenderness, but absence of hypertrichosis ([Fig. 1](#g001){ref-type="fig"}). A hematological examination showed a white blood cell count of 5.8×10^9^/L with a normal differential count, a hemoglobin concentration of 10.1 g/dL, and a platelet count of 56×10^9^/L. The patient was in renal failure, with a serum creatinine level of 1.30 mg/dL. Serum VEGF, plasma VEGF, and serum interleukin-6 (IL-6) concentrations were elevated to 1,790 pg/mL, 1,120 pg/mL, and 9.1 pg/mL, respectively. In addition, endocrine abnormalities, such as elevation of luteinizing hormone, follicle-stimulating hormone, and prolactin, were observed ([Table 1](#t001){ref-type="table"}). IgG-kappa-type monoclonal protein was observed by serum protein immunofixation, but serum IgG levels were normal. A urinalysis revealed albuminuria, but Bence-Jones protein was not observed.

![Skin changes. (A) Glomeruloid hemangioma and gynecomastia. (B) Hyperpigmentation and peripheral edema of the foot. (C) White nails.](1349-7235-58-3461-g001){#g001}

###### 

Laboratory Findings on Admission.

  ------------- ------- -------------- ----- -------------------- ------- ----------- --------- ------------------------ ------- ------- ------ --------------- ------- -------------- -- ------------
  Hematology            Biochemistry         Immunological test           Cytokines             Normal range                                                                              
  WBC           5.8     ×10^9^/L             AST                  19      U/L                   CRP                      2.81    mg/dL          plasma VEGF     1,120   pg/mL             \<38.3
  Neut          70.8    \%                   ALT                  11      U/L                   sIL-2R                   1,390   U/mL           serum VEGF      1,790   pg/mL             NA
  Lym           15.5    \%                   ALP                  217     U/L                   β2-MG                    6.7     µg/mL          serum IL-6      9.1     pg/mL             \<4.0
  Mono          8.4     \%                   LDH                  215     U/L                   ACE                      12.0    U/mL           serum TNF-α     3.87    pg/mL             0.75-1.66
  Eo            4.3     \%                   γ-GTP                130     U/L                   Lysozyme                 13.1    µg/mL                                                    
  Baso          1.0     \%                   TP                   6.6     g/dL                  C3                       115     mg/dL          Endocrinology           Normal range      
  RBC           3.51    ×10^12^/L            Alb                  3.6     g/dL                  C4                       32      mg/dL          LH              30.5    mIU/mL            0.79-5.72
  Hb            10.1    g/dL                 T-Bil                0.4     mg/dL                 CH50                     \>60    U/mL           FSH             56.9    mIU/mL            2.00-8.30
  Ht            29.6    \%                   T-Cho                132     mg/dL                 IgG                      1,199   mg/dL          ACTH            54.5    pg/mL             7.2-63.3
  Plt           56      ×10^9^/L             TG                   97      mg/dL                 IgA                      155     mg/dL          Cortisol        9.6     µg/dL             6.2-18
  MCV           84.3    fl                   LDL-C                74      mg/dL                 IgM                      101     mg/dL          Prolactin       80.40   ng/mL             4.29-13.69
  MCHC          34.1    \%                   BUN                  21.1    mg/dL                 FLCκ                     155     mg/L           intact PTH      33      pg/mL             10-65
  Ret           19.1    ‰                    UA                   8.9     mg/dL                 FLCλ                     44.4    mg/L           FT3             3.0     pg/mL             2.2-3.3
                                             Cre                  1.30    mg/dL                 κ/λ                      3.49                   FT4             1.8     ng/dL             0.8-1.6
  Coagulation           CK             63    IU/L                         IgG4        26.0      mg/dL                            TSH     3.41   µIU/mL                  0.38-4.31         
  APTT          30.7    s                    AMY                  64      U/L                   ANA                      40      ×                                                        
  PT            11.6    s                    ChE                  156     U/L                                            SP+HO                  Infection                                 
  PT-INR        1.00                         Ca                   8.5     mg/dL                 RNP                      2.3     U/mL           IGRA            (-)                       
  FDP           7.00    µg/mL                iP                   4.8     mg/dL                 SS-A                     0.7     U/mL           HBsAg           (-)                       
  Fibrinogen    423     mg/dL                Na                   141     mEq/L                 Scl-70                   1.8     U/mL           HCV             (-)                       
  ATIII         92.9    \%                   K                    4.1     mEq/L                 Jo-1                     9.3     U/mL           TPHA            (-)                       
  D-dimer       1.75    µg/mL                Cl                   107     mEq/L                 PR3-ANCA                 \<1.0   U/mL           RPR             (-)                       
  ProteinC      76.1    \%                   Fe                   35      µg/dL                 MPO-ANCA                 \<1.0   U/mL                                                     
  ESR 1h        41      mm                   TIBC                 204     µg/dL                 RF                       4       IU/mL                                                    
  ESR 2h        59      mm                   UIBC                 169     µg/dL                                                                                                           
                                             Ferritin             207     ng/mL                 Bone marrow aspiration                                                                    
  Urinalysis            Transferrin    154   mg/dL                        NCC         161,300   /µL                                                                                       
  UP            (+)                          Cys-C                2.45    mg/L                  MegK                     109.4   /µL                                                      
                0.276   g/gCre               Glu                  92      mg/dL                 Plasma cell              1.2     \%                                                       
  OB            (-)                          HbA1c                4.9     \%                    G-BAND                   46,XY                                                            
  WBC           (-)                          BNP                  83.1    pg/mL                 FISH                                                                                      
  β2-MG         28.0    µg/L                 VB12                 1,163   pg/mL                 del17p                   (-)                                                              
  NAG           14.5    IU/L                                                                    IgH/FGFR3                (-)                                                              
                                                                                                IgH/MAF                  (-)                                                              
  ------------- ------- -------------- ----- -------------------- ------- ----------- --------- ------------------------ ------- ------- ------ --------------- ------- -------------- -- ------------

WBC: white blood cell, Neut: neutrophil, Lym: lymphocyte, Mono: monocyte, Eo: eosinophil, Baso: basophil, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, Plt: platelet, MCV: mean corpuscular volume, MCHC: mean corpuscular hemoglobin concentration, Ret: reticulocyte, APTT: activated partial thromboplastin time, PT: prothrombin time, PT-INR: prothrombin time-international normalized ratio, FDP: fibrin-fibrinogen degradation products, ATIII: antithrombin III, ESR: erythrocyte sedimentation rate, UP: urine protein, OB: occult blood, β2-MG: β2-microglobulin, NAG: N-acetyl glucosaminidase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, γ-GTP: γ-glutamyl transpeptidase, TP: total protein, Alb: albumin, T-Bil: total bilirubin, T-Cho: total cholesterol, TG: triglyceride, LDL-C: low density lipoprotein-cholesterol, BUN: blood urea nitrogen, UA: uric acid, Cre: creatinine, CK: creatine kinase, AMY: amylase, ChE: cholinesterase, Ca: calcium, iP: inorganic phosphorus, Na: sodium, K: potassium, Cl: chloride, Fe: serum iron, TIBC: total iron binding capacity, UIBC: unsaturated iron binding capacity, Cys-C: cystatin-C, Glu: glucose, BNP: brain natriuretic peptide, VB12: vitamin B12, CRP: C-reactive protein, sIL-2R: soluble interleukin-2 receptor, ACE: angiotensin converting enzyme, CH50: 50% hemolytic unit of complement, IgG: immunoglobulin G, IgA: immunoglobulin A, IgM: immunoglobulin M, FLC: free light chain, ANA: anti-nuclear antibody, SP: speckled pattern, HO: homogeneous pattern, RNP: ribonucleoprotein, PR3-ANCA: proteinase3 anti-neutrophil cytoplasmic antibody, MPO-ANCA: myeroperoxidase anti-neutrophil cytoplasmic antibody, RF: rheumatoid factor, NCC: nucleated cell count, MegK: megakaryocyte, FISH: fluorescence in situ hybridization, VEGF: vascular endothelial growth factor, NA: not available, IL-6: Interleukin-6, TNF-α: tumor necrosis factor-α, LH: luteinizing hormone, FSH: follicle stimulating hormone, ACTH: adrenocorticotropic hormone, PTH: parathyroid hormone, FT3: free triiodothyronine, FT4: free thyroxine, TSH: thyroid stimulating hormone, IGRA: interferon-gamma release assay, HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, TPHA: treponema pallidum hemagglutination test, RPR: rapid plasma reagin

An ultrasound examination showed pericardial effusion of about 400 mL, but the ejection fraction was normal. Whole-body computed tomography showed pleural effusion and pelvic bone sclerosis but no lymphadenopathy, hepatomegaly, or splenomegaly ([Fig. 2](#g002){ref-type="fig"}). Positron emission tomography did not reveal any tumorous accumulation. A nerve conduction study showed polyneuropathy with dominant axonal degeneration accompanied by a decrease in nerve conduction velocity, extension of distant latency, and reduction of compound muscle action potential. Bone marrow aspiration showed 1.2% plasma cells, sometimes associated with atypia ([Fig. 3A](#g003){ref-type="fig"}). An increase was observed in the number of megakaryocytes (109.4 /μL) without atypia. IgG-kappa-type monoclonal protein was also recognized by immunofixation of bone marrow blood ([Fig. 3B](#g003){ref-type="fig"}). MFC (DuraClone, Beckman Coulter, Brea, USA; [Table 2](#t002){ref-type="table"}) showed 0.2% neoplastic plasma cells with kappa chains ([Fig. 3C](#g003){ref-type="fig"}). A percutaneous kidney biopsy revealed membranoproliferative glomerulonephritis (MPGN)-like changes, but there was no deposition of immunoglobulins or light chains ([Fig. 4](#g004){ref-type="fig"}). Amyloidosis was not observed on a bone marrow biopsy, skin biopsy, renal biopsy, or intestinal biopsy.

![Computed tomography (CT) and chest X-ray. (A) Osteosclerotic lesion on the right side of the pelvis (white arrow). (B) Chest X-ray before lenalidomide-dexamethasone (Ld) treatment showing bilateral pleural effusion (left panel) and on day 13 of Ld therapy showing complete resolution of pleural effusion (right panel).](1349-7235-58-3461-g002){#g002}

![Bone marrow aspiration. (A) The smear showing atypical plasma cells. (B) Immunofixation electrophoresis confirmed IgG-kappa monoclonal gammopathy (white arrows). (C) A multiparameter flow cytometry analysis (DuraClone) showing neoplastic plasma cells with kappa light chain. Blue dots: normal plasma cells, purple dots: neoplastic plasma cells.](1349-7235-58-3461-g003){#g003}

###### 

Antibodies of the Used DuraClone Panels.

  Tube No.      Pacific Blue      Krome Orange      FITC      PE          PC5.5      PC7        APC        APC-A750
  ---------- -- -------------- -- -------------- -- ------ -- -------- -- ------- -- ------- -- ------- -- ----------
  1             CD38              CD45              CD81      CD27        CD19       CD200      CD138      CD56
  2             CD45              CD138             CD38      Lambda      CD56       CD19       Kappa      \-

![Renal pathological findings. Light microscopy of a hypertrophic glomerulus shows mesangial matrix expansion, narrowing of the glomerular capillary loops, and double contour of the glomerular basement membrane (arrows). Periodic acid-Schiff staining (original magnification ×400).](1349-7235-58-3461-g004){#g004}

Since the diagnostic criteria of the Mayo Clinic ([@B9]) were satisfied, we finally diagnosed the patient with POEMS syndrome. Because of anemia, thrombocytopenia, and C-reactive protein positivity, overlap with Castleman\'s disease was considered. However, because there were no enlarged lymph nodes, we excluded Castleman\'s disease. The patient also met the diagnostic criteria for the recently proposed TAFRO syndrome as he tested positive for fluid retention, thrombocytopenia, high inflammatory response, megakaryocytic hyperplasia, and progressive kidney failure. However, our case showed the presence of monoclonal protein and an abnormality in the nerve conduction test, so TAFRO syndrome was excluded.

In order to avoid inducing peripheral neuropathy with thalidomide, we chose lenalidomide 10 mg/day and dexamethasone 20 mg/week (Ld) therapy. In accordance with our institutional regulations, all treatments in this case were provided with the approval of the institutional review board and the consent of the patient. Pleural effusion and limb pain quickly improved after treatment was started. In addition, we observed the recovery of the platelet counts, improvement of the renal function, and reduction of the inflammatory response. The treatment efficacy parameters, as evaluated by the Mayo Clinic criteria ([@B10]) after two courses of Ld therapy, were as follows: hematologic response, could not be evaluated; VEGF response, partial VEGF response (PR~V~); clinical response, clinical improvement (I~C~); and PET response, could not be evaluated. MFC showed a reduction in the fraction of neoplastic plasma cells, confirming the therapeutic effect ([Fig. 5](#g005){ref-type="fig"}). The patient was transferred to a hospital near his residence and continued to receive Ld therapy. The dexamethasone dose was reduced because he developed sleeplessness; however, his symptoms did not relapse after dose reduction. Plasma VEGF levels also did not change.

![Clinical course. (A) The illustration shows changes in C-reactive protein (CRP), platelets (Plt) and creatinine (Cre) with lenalidomide-dexamethasone (Ld) therapy. (B) The values of neoplastic plasma cells (PCs), free light chain (FLC), and vascular endothelial growth factor (VEGF) before treatment and after two courses of Ld therapy are shown. Antigens in tube 1 and tube 2 are shown in [Fig. 3C](#g003){ref-type="fig"} and [Table 2](#t002){ref-type="table"}.](1349-7235-58-3461-g005){#g005}

Discussion
==========

The detection of MRD has become very important in the treatment of hematological malignancies ([@B11]). Generally, MFC is a method for detecting MRD by identifying tumor-specific surface antigens using antibodies labeled with four or more color fluorochromes. In the present case, MFC identified small amounts of neoplastic plasma cells, which are characteristic of POEMS syndrome. As shown in [Table 3](#t003){ref-type="table"}, it was observed that the surface antigen profile of neoplastic plasma cells in this case (CD27 negative, CD19 negative, CD56 positive, and CD81 diminished) was more similar to that of myeloma cells than to that of monoclonal gammopathy of undetermined significance (MGUS) ([@B12]-[@B14]). This suggests that neoplastic plasma cells of POEMS syndrome (even in small numbers) are malignant.

###### 

Surface Antigen Profiles of Plasma Cell Neoplasms.

  Antigen      Normal PC      MGUS         MM              Present case (POEMS)
  --------- -- ----------- -- --------- -- ------------ -- ----------------------
  CD138        \+             \+           \+              \+
  CD38         \+             \+           \+              \+
  CD56         \-             \- or +      \+              \+
  CD19         \+             dim+         \- or dim+      \-
  CD45         \+             \- or +      \- or dim+      dim+
  CD200        \-             \- or +      \+              \+
  CD81         \+             \- or +      \- or dim+      dim+
  CD27         \+             \+           \- or dim+      \-

PC: plasma cell, MGUS: monoclonal gammopathy of undetermined significance, MM: multiple myeloma

It has been reported that CD27, which was decreased in the present case, does not decrease in cases of MGUS but does decrease in cases of MM ([@B12],[@B15]). Negative CD27 is considered to indicate a poor prognosis in MM ([@B15],[@B16]). However, the relationship between the surface antigen profile of neoplastic plasma cells and the therapeutic reactivity/prognosis in POEMS syndrome has not been clarified, so further research is necessary. In addition, in most cases of POEMS syndrome, the proportion of neoplastic plasma cells is lower than that in MM. Therefore, MRD detection by MFC seems to be very useful for the diagnosis and follow-up of POEMS syndrome, in addition to assessments of the clinical symptoms and VEGF values.

Since serum VEGF is strongly influenced by the level of platelets, it is recommended that plasma VEGF levels be used to evaluate the therapeutic effect ([@B10],[@B17]). Indeed, serum VEGF levels have been reported to be over 10 times higher than plasma VEGF levels because of the release of VEGF from activated or aggregated platelets ([@B18]). Therefore, we used plasma VEGF levels to evaluate the therapeutic effect in our patient with thrombocytopenia.

Almost all patients with POEMS syndrome have the lambda-type monoclonal protein ([@B19]-[@B21]). This is because monoclonal proteins have a specific V lambda subfamily gene that can cause high cytokinemia involving cytokines, such as VEGF via some signals ([@B22]). However, the mechanism has not been fully elucidated. In contrast, POEMS syndrome with kappa-type monoclonal protein is very rare. [Table 4](#t004){ref-type="table"} shows the details of five POEMS syndrome cases with kappa-type monoclonal protein, including our own ([@B23]-[@B26]). All patients showed some endocrine abnormality. Interestingly, renal failure was a complication in three cases, including our own. It has been reported that about 20% of POEMS syndrome cases have associated renal dysfunction ([@B27]). In our earlier study, we reported the clinicopathological features of 52 patients with POEMS syndrome with renal complications. Over half of the patients had renal dysfunction with serum creatinine \>1.5 mg/dL, and 10% of the patients needed renal replacement therapy. The histological findings of the kidney in POEMS syndrome frequently include MPGN-like glomerular changes, such as glomerular swelling, mesangial proliferation, mesangiolysis, and endothelial and mesangial cell enlargement ([@B28]). These glomerular changes are thought to be caused by cytokines, such as VEGF and IL-6 ([@B29]). Nephropathy in POEMS syndrome is significantly improved by treatment with new agents, including lenalidomide, compared to treatment without these agents ([@B27]). In our case, Ld therapy improved the renal function as plasma VEGF levels decreased. For patients with renal dysfunction, it is necessary to reduce the dose of lenalidomide in order to prevent hematologic toxicity and maintain optimal plasma concentrations ([@B30]). Lenalidomide can be safely used in patients with POEMS syndrome with renal dysfunction.

###### 

Clinical Findings and Therapies in Patients with Kappa-type Monoclonal Protein.

  -------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                         \#1 (23)    \#2 (24)        \#3 (25)        \#4 (26)    \#5 (present case)   \% Affected (9)
  -------------------------------------- ----------- --------------- --------------- ----------- -------------------- -----------------
  Sex/Age, Years                         M/64        M/57            F/50            M/60        M/72                 

  Polyneuropathy                         \+          \+              \+              \+          \+                   100

  demyelinating or axonal degeneration   mixed       demyelinating   demyelinating   ?           mixed                

  Organomegaly                           \-          \+              ?               \+          \-                   45-85

  Hepatomegaly                           \-          \+              ?               ?           \-                   24-78

  Splenomegaly                           \-          \+              ?               \+          \-                   22-70

  Lymphadenopathy                        \-          ?               ?               \-          \-                   26-74

  Castleman's disease                    ?           ?               ?               ?           \-                   11-25

  Endocrinopathy                         \+          \+              \+              \+          \+                   67-84

  Gonadal axis abnormality               \+          ?               ?               \+          \+                   55-89

  Adrenal axis abnormality               ?           ?               ?               ?           \-                   16-33

  Increased prolactin value              ?           ?               ?               ?           \+                   5-20

  Gynecomastia or galactorrhea           \+          \+              ?               ?           \+                   12-18

  Diabetes mellitus                      \+          \-              \+              ?           \-                   3-36

  Hypothyroidism                         \-          \+              ?               ?           \-                   9-67

  M protein                              \+          \+              \+              \+          \+                   100

  Monoclonal plasma cell dyscrasia       \+          \+              \+              \+          \+                   100

  M protein on serum electrophoresis     \+          \+              \+              \+          \+                   24-54

  M protein type                         IgG-kappa   IgG-kappa       IgG-kappa       IgG-kappa   IgG-kappa            

  Plasma cells in bone marrow            1.0%        no increase     7.6%            20.0%       1.2%                 \<5%

  Bone lesions                           \+          \-              \+              \-          \+                   27-97

  Skin changes                           \+          \+              \+              \-          \+                   68-89

  Hyperpigmentation                      \+          ?               \+              \-          \+                   46-93

  Acrocyanosis and plethora              \+          \+              ?               \-          \+                   19

  Hemangioma/telangiectasia              ?           ?               ?               \-          \+                   9-35

  Hypertrichosis                         \+          ?               \+              \-          \-                   26-74

  Thickening                             \+          ?               ?               \-          \+                   5-43

  Clubbing                               \+          ?               ?               ?           \-                   5-49

  Extravascular volume overload          \+          \+              ?               \+          \+                   29-87

  Peripheral edema                       \+          \+              ?               ?           \+                   24-89

  Ascites                                \-          ?               ?               \+          \-                   7-54

  Pleural effusion                       \-          ?               ?               \+          \+                   3-43

  Pericardial effusion                   \-          ?               ?               \+          \+                   1-64

  Nephropathy                            ?           \+              ?               \+          \+                   NA

  renal failure                          ?           \+              ?               \+          \+                   NA

  renal biopsy                           ?           MPGN-like       ?               FSGS        MPGN-like            

  Other signs                                                                                                         

  Thrombocytosis                         ?           ?               ?               \-          \-                   54-88

  Thrombotic diatheses                   ?           ?               ?               \+          \+                   NA

  Polycythemia                           \-          \-              \-              \-          \-                   12-19

  Papilledema                            ?           ?               ?               ?           \-                   29-64

  Decreased DLCO                         ?           ?               ?               ?           ?                    \>15

  Pulmonary hypertension                 ?           ?               ?               ?           ?                    36

  Weight loss                            ?           \+              ?               ?           ?                    37

  hyperhidrosis                          \-          ?               \+              \+          \-                   NA

  Fatigue                                ?           \+              \+              ?           \+                   31

  Therapy                                MP          IVIG/PSL/CY/\   Ld              CyA+PSL/\   Ld                   
                                                     mPSLpulse                       VCD/VTD                          
  -------------------------------------------------------------------------------------------------------------------------------------

In conclusion, our case suggested that identification of neoplastic plasma cells by MFC is important for obtaining a proper diagnosis and enacting treatment of POEMS syndrome. In the future, MFC will be essential for the treatment of this syndrome. Ld therapy might be effective in cases of POEMS syndrome for reducing VEGF levels. It is also important to clarify the cause of kidney dysfunction by a renal biopsy in POEMS syndrome patients with renal failure. Furthermore, since POEMS syndrome with kappa-type monoclonal protein is very rare, it is necessary to increase our knowledge about its clinical presentation and therapeutic reactivity.

**The authors state that they have no Conflict of Interest (COI).**

[^1]: Correspondence to Dr.　Sho Ikeda, <sikeda@med.akita-u.ac.jp>
